Cargando…
Latest Approved Therapies for Metastatic Melanoma: What Comes Next?
Nowadays, oncogene-directed therapy and immunotherapy represent the two most promising avenues for patients with metastatic melanoma. The recent oncogene-directed therapeutic, vemurafenib, usually produces high level of tumor shrinkage and survival benefits in many patients with B-RAF (V600E) mutant...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3595667/ https://www.ncbi.nlm.nih.gov/pubmed/23533766 http://dx.doi.org/10.1155/2013/735282 |
_version_ | 1782262438255656960 |
---|---|
author | Menaa, Farid |
author_facet | Menaa, Farid |
author_sort | Menaa, Farid |
collection | PubMed |
description | Nowadays, oncogene-directed therapy and immunotherapy represent the two most promising avenues for patients with metastatic melanoma. The recent oncogene-directed therapeutic, vemurafenib, usually produces high level of tumor shrinkage and survival benefits in many patients with B-RAF (V600E) mutant melanomas, although the fast and high degrees of responses are likely short-lived. Conversely, the newly-approved immunotherapeutic, ipilimumab, produces durable responses in patients presenting CTLA-4 T-cell surface protein. Nevertheless, the possible synergy in combining these two therapeutic strategies primarily rely on the rational design of medical protocols (e.g., sequence and timing of agent administration; drug selectivity; compatibility of combined therapies i.e., adoptive T cell or agents, i.e., MEK inhibitor trametinib, PD-1 and PDL-1 blockers). Improved therapeutic protocols shall overcome therapeutic limitations such as the (i) tolerability and safety (i.e., minimal toxic side-effects); (ii) progression free survival (e.g., reduced relapse disease frequency); (iii) duration response (i.e., decreased drug resistance). Eventually, multidisciplinary approaches are still requested (e.g., genomics for personalized medicine, nanomedicine to overcome low free-drug bioavailability and targeting, systematic search of “melanoma stem cells” to enhance the prognosis and develop more valuable theranostics). In this paper, I will mainly present and discuss the latest and promising treatments for advanced cutaneous melanomas. |
format | Online Article Text |
id | pubmed-3595667 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-35956672013-03-26 Latest Approved Therapies for Metastatic Melanoma: What Comes Next? Menaa, Farid J Skin Cancer Review Article Nowadays, oncogene-directed therapy and immunotherapy represent the two most promising avenues for patients with metastatic melanoma. The recent oncogene-directed therapeutic, vemurafenib, usually produces high level of tumor shrinkage and survival benefits in many patients with B-RAF (V600E) mutant melanomas, although the fast and high degrees of responses are likely short-lived. Conversely, the newly-approved immunotherapeutic, ipilimumab, produces durable responses in patients presenting CTLA-4 T-cell surface protein. Nevertheless, the possible synergy in combining these two therapeutic strategies primarily rely on the rational design of medical protocols (e.g., sequence and timing of agent administration; drug selectivity; compatibility of combined therapies i.e., adoptive T cell or agents, i.e., MEK inhibitor trametinib, PD-1 and PDL-1 blockers). Improved therapeutic protocols shall overcome therapeutic limitations such as the (i) tolerability and safety (i.e., minimal toxic side-effects); (ii) progression free survival (e.g., reduced relapse disease frequency); (iii) duration response (i.e., decreased drug resistance). Eventually, multidisciplinary approaches are still requested (e.g., genomics for personalized medicine, nanomedicine to overcome low free-drug bioavailability and targeting, systematic search of “melanoma stem cells” to enhance the prognosis and develop more valuable theranostics). In this paper, I will mainly present and discuss the latest and promising treatments for advanced cutaneous melanomas. Hindawi Publishing Corporation 2013 2013-02-24 /pmc/articles/PMC3595667/ /pubmed/23533766 http://dx.doi.org/10.1155/2013/735282 Text en Copyright © 2013 Farid Menaa. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Menaa, Farid Latest Approved Therapies for Metastatic Melanoma: What Comes Next? |
title | Latest Approved Therapies for Metastatic Melanoma: What Comes Next? |
title_full | Latest Approved Therapies for Metastatic Melanoma: What Comes Next? |
title_fullStr | Latest Approved Therapies for Metastatic Melanoma: What Comes Next? |
title_full_unstemmed | Latest Approved Therapies for Metastatic Melanoma: What Comes Next? |
title_short | Latest Approved Therapies for Metastatic Melanoma: What Comes Next? |
title_sort | latest approved therapies for metastatic melanoma: what comes next? |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3595667/ https://www.ncbi.nlm.nih.gov/pubmed/23533766 http://dx.doi.org/10.1155/2013/735282 |
work_keys_str_mv | AT menaafarid latestapprovedtherapiesformetastaticmelanomawhatcomesnext |